In addition, manipulating SIGIRR expression in cancer cells may help to relieve IL1-mediated RCC activation and may complement the use of targeted drugs as well as checkpoint inhibitors; at the same time, a careful analysis of SIGIRR expression along markers of intrinsic cancer cell inflammation may help to dissect tumor heterogeneity as well as immunotherapy response, which is becoming pivotal in the clinical management of advanced and metastatic RCC. The gene discussed is IL1B; the disease is renal cell carcinoma.